Oxcarbazepine Versus Placebo in Childhood Autism

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The proposed study is designed to assess the effectiveness of treatment with Oxcarbazepine vs. placebo in childhood/adolescent autism. This is a twelve-week study involving twenty subjects between the ages of five and seventeen with a diagnosis of autism.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Medicine and Dentistry of New Jersey
• Collaborator: National Alliance for Research on Schizophrenia and Depression
• Treatments: Carbamazepine; Oxcarbazepine

Criteria

Inclusion Criteria:

• Subject has autism.

• Subject is between five and seventeen years of age

• Subject is not hospitalized.

Exclusion Criteria:

• Subject has been diagnosed with a psychopathic disorder or a mood disorder, including depression or bipolar disorder.

• Subject has displayed self-injurious behavior.

• Subject has an active seizure disorder or epilepsy.

• Subject has an unstable medical illness.

• Subject has undergone brain injury.

• Subject has a history of diabetes.

• Subject has a history of prior treatment with oxcarbazepine of 600 mg/day for 6 weeks.

• Subject has used other study drugs within the previous 30 days.

• Subject is a pregnant female or unwilling to use acceptable contraception if sexually active.